Loading peptide…
PeptideChat is for educational and research purposes only. Nothing on this site constitutes medical advice. Peptides are sold as research chemicals only and are not intended for human use. These statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. PeptideChat is an independent educational resource — not a pharmacy, compounding, or 503A/503B outsourcing facility — and does not sell products or provide medical advice.
Also known as: Trevogrumab
Trevogrumab (REGN1033) is an investigational fully human monoclonal antibody that binds and neutralizes myostatin (GDF-8). It has been studied as an anti-myostatin therapy aimed at preserving or increasing skeletal muscle mass. Note: Trevogrumab is a monoclonal antibody (anti-myostatin), not a peptide; included here for reference.
Sign in to rate this peptide.
Trevogrumab is an IgG4 monoclonal antibody that selectively binds mature myostatin (growth differentiation factor 8), preventing it from engaging the activin type IIB receptor (ActRIIB). Myostatin normally signals through ActRIIB and the ALK4/ALK5 receptors to activate SMAD2/3, which transcriptionally restrains muscle fiber growth. By sequestering circulating myostatin, the antibody relieves this brake, shifting the balance toward muscle protein accretion and hypertrophy. Because it targets myostatin specifically rather than the shared receptor, it is intended to spare related TGF-beta family signaling.